{"id":380188,"date":"2020-11-12T16:04:12","date_gmt":"2020-11-12T21:04:12","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=380188"},"modified":"2020-11-12T16:04:12","modified_gmt":"2020-11-12T21:04:12","slug":"capricor-therapeutics-reports-third-quarter-2020-financial-results-and-provides-corporate-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-reports-third-quarter-2020-financial-results-and-provides-corporate-update\/","title":{"rendered":"Capricor Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update"},"content":{"rendered":"
\n

\n
\n Exosome Platform <\/em>
\n <\/strong>
\n
\n Technology
<\/em>
\n <\/strong>
\n -Announced Positive Preclinical Data <\/em>
\n for Multivalent Exosome-mRNA Vaccine For COVID-19-
<\/em>
\n –<\/em>
\n Novel <\/em>
\n Vaccine <\/em>
\n Induce<\/em>
\n d<\/em>
\n Long-Lasting Immunity to Multiple SARS-CoV-2 Proteins<\/em>
\n –
<\/em>
\n -Development of Safe, Non-toxic Exosome Formulation Capable of Delivering Functional mRNA in vitro and in vivo-
<\/em>
\n –<\/em>
\n Platform Expansion Underway Using Engineered Exosomes<\/em>
\n –<\/em>\n <\/p>\n

\n
\n Duchenne Muscular Dystrophy Program<\/em>
\n <\/strong>
\n
\n -In Discussions with FDA on Next Steps in Pathway Forward-<\/em>\n <\/p>\n

\n
\n CAP-1002 for COVID-19<\/em>
\n <\/strong>
\n
\n –<\/em>
\n P<\/em>
\n atient <\/em>
\n S<\/em>
\n creening <\/em>
\n U<\/em>
\n nderway<\/em>
\n in Randomized, Double-Blind, Placebo-Controlled INSPIRE Study-<\/em><\/p>\n

–<\/em>
\n To Host Conference Call and Webcast <\/em>
\n Today<\/em>
\n at 4:30 p.m. ET<\/em>
\n –<\/em>\n <\/p>\n

LOS ANGELES, Nov. 12, 2020 (GLOBE NEWSWIRE) — Capricor Therape<\/u>u<\/u>tics, Inc.<\/u><\/a> (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class cell and exosome-based therapeutics for the treatment and prevention of a variety of diseases and disorders, announced today its financial results for the third quarter ending September 30, 2020 and provided a corporate update.<\/p>\n

\u201cThe Company\u2019s development and achievements in the third quarter have been encouraging on multiple levels. We have continued to build momentum with our exosome platform technology as well as with our CAP-1002 program. The pandemic has provided a unique opportunity for the development of a vaccine candidate but also for the use of CAP-1002 as a potential therapeutic,\u201d said Linda Marb\u00e1n, Ph.D., Capricor\u2019s president and chief executive officer.\u00a0<\/p>\n

\u201cWe are advancing two separate and novel vaccine programs. Our strategy has evolved from our original plan to use exosomes from our cell as drug delivery vehicles to creating exosomes from multiple cell types that are readily available to build products that can be designed to address targets where delivery has proved to be challenging. We are now leveraging thought leaders and our own expertise to direct the development of exosome-based vaccines and exosome-based therapeutics. We expect significant pipeline expansion and will be seeking partnering opportunities in the months ahead to further cement our rebranding. I have never been more excited at the possibilities for Capricor,\u201d Dr. Marb\u00e1n added.<\/p>\n

The Company continues the development of our late-stage clinical asset, CAP-1002, for the treatment of advanced stages of DMD, and is currently in discussions with potential partners for this program. The FDA has continued to encourage us to conduct a Phase III study, however at this time, Capricor continues to work with FDA to explore alternative pathways forward.<\/p>\n

Capricor is currently screening patients for its INSPIRE Phase II study, which is designed to assess the ability of CAP-1002 to modulate the cytokine storm and attenuate the sequelae associated with severe COVID-19. While other therapeutics are in testing for early and much later stage COVID-19, there are very few options for those with severe disease at risk for ventilation. Based on our preclinical data, as well as the data from our emergency use authorization program, CAP-1002 is poised to potentially be an important tool in the toolbox to treat severe COVID-19.<\/p>\n

\u201cWe are pleased to deliver an update of those accomplishments today focused on our engineered exosome platform, DMD and COVID-19 programs and our anticipated milestones,\u201d added Dr. Marb\u00e1n.<\/p>\n

\n Third <\/strong>
\n Quarter<\/strong>
\n Highlights and Recent Developments<\/strong>\n <\/p>\n

\n
\n Engineered <\/em>
\n <\/strong>
\n
\n Exosome<\/em>
\n <\/strong>
\n
\n s<\/em>
\n <\/strong>
\n
\n Platform <\/em>
\n <\/strong>\n <\/p>\n